Rapid Influenza Diagnostic Testing (RIDT) Market Industry Status, Sales Overview, Supply-demand 2021-2026 - PowerPoint PPT Presentation

About This Presentation
Title:

Rapid Influenza Diagnostic Testing (RIDT) Market Industry Status, Sales Overview, Supply-demand 2021-2026

Description:

Seasonal influenza continues to be one of the most common, and serious health conditions seen worldwide that even stands as a leading cause of mortality. The need for rapid critical diagnosis thus prevails, pushing the growth of rapid influenza diagnostic testing (RIDT) market. – PowerPoint PPT presentation

Number of Views:6

less

Transcript and Presenter's Notes

Title: Rapid Influenza Diagnostic Testing (RIDT) Market Industry Status, Sales Overview, Supply-demand 2021-2026


1
Rapid Influenza Diagnostic Testing Market Grows
Strong with Surge in Adoption of RIDT as a
Preferred POCT Form Seasonal influenza continues
to be one of the most common, and serious health
conditions seen worldwide that even stands as a
leading cause of mortality. The need for rapid
critical diagnosis thus prevails, pushing the
growth of rapid influenza diagnostic testing
(RIDT) market. One of the recent studies of
Fairfield Market Research focuses on the growth
prospects of global rapid influenza diagnostic
testing market over the next few years. Adoption
of RIDT as a preferred point-of-care testing
(POCT) form has been on the rise over the recent
past, which is expected to largely contribute to
market growth. The accuracy, and faster outcome
of rapid influenza diagnostic testing also will
remain the critical growth contributor for
market. With the diagnostics sector poised for a
flourishing growth outlook, demand for rapid
influenza diagnostic testing will also thrive.
The report suggests that paediatrics will be an
important segment for RIDT market players. Get
Exclusive PDF Sample Copy Of This Report_at_
https//www.fairfieldmarketresearch.com/report/rap
id-influenza-diagnostic-testing-ridt-
market/request-sample Demand for RIDT Received a
Dramatic Push amid COVID-19 Pandemic While
influenza A and B prevalence remains on an
all-time high, it has also been responsible for
the recent epidemics such as avian/bird flu. This
highlights the need for an effective diagnostic
measure, as well as early treatment against all
the flu variants. The constant quest for a
specific, reliable treatment will remain the key
factor accelerating adoption of rapid influenza
diagnostic testing methods. COVID-19 pandemic
particularly generated robust demand for RIDT
for its higher specificity, faster outcome,
convenient usage, and greater sensitivity.
Hospitals, and diagnostic centres continue to
record consumption at healthy rates, thereby
favouring the growth of rapid influenza
diagnostic testing market. Striking resemblance
between the symptoms of flue, and COVID-19
initially gave a solid push to flu
testing. North America Dominant, Sales of RIDT
Kits Prominent in Asia Pacific There has been a
lot of effort from governments in North America
toward public education, and awareness about flu
diagnosis, and treatment. While this will
continue to drive North American market for
rapid influenza diagnostic testing, predominant
technology penetration in the US is also likely
to be an important factor fuelling market growth
here. The region houses a dynamic research field
that also favours the growth of market. Both the
US, and Canada witness a notably high number of
hospitalisation cases each year, creating revenue
generation opportunities for RIDT market
participants. Asia Pacific on the other hand
holds high-value opportunities according to
initial report findings. Besides increasing
prevalence of flu, this market will benefit from
the growth of high-risk elderly population. RIDT
kits continue to gain traction in key Asian
markets.
2
Key Competitors in Rapid Influenza Diagnostic
Testing Market Hologic, Thermo Fisher Scientific
Inc., Becton, Dickinson and Company, Abbott
Laboratories, GenMark Diagnostics, Inc., Danaher
Corporation (Cepheid), F. Hoffmann-La Roche Ltd.,
Quidel Corporation, Luminex Corporation,
Meridian Bioscience, Inc., Biocartis, bioMérieux
Inc., and EndressHauser (Analytik Jena AG)
constitute some of the prominent companies
driving competition in global rapid influenza
diagnostic testing market. Fairfield Market
Research intends to shed light on the detailed
competitive profiling in the report that would
help existing, and potential competitors in RIDT
market landscape. Check Complete Report Details
of market _at_ https//www.fairfieldmarketresearch.c
om/report/rapid-influenza-diagnostic-testing-ridt-
market/request-sample About Us Fairfield
Market Research is a UK-based market research
provider. Fairfield offers a wide spectrum of
services, ranging from customized reports to
consulting solutions. With a strong European
footprint, Fairfield operates globally and helps
businesses navigate through business cycles,
with quick responses and multi-pronged
approaches. The company values an eye for
insightful take on global matters, ably backed by
a team of exceptionally experienced researchers.
With a strong repository of syndicated market
research reports that are continuously published
updated to ensure the ever-changing needs of
customers are met with absolute
promptness. Contact Fairfield Market
Research London, UK UK 44 (0)20 30025888 USA 1
(844) 3829746 (Toll-free) Web https//www.fairfie
ldmarketresearch.com/ Email sales_at_fairfieldmarket
research.com Follow Us LinkedIn
Write a Comment
User Comments (0)
About PowerShow.com